BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Povitz M, Li L, Hosein K, Shariff S, Mura M. Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization. Pulm Pharmacol Ther 2019;56:94-9. [PMID: 30930173 DOI: 10.1016/j.pupt.2019.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res 2022;23:3. [PMID: 34996465 DOI: 10.1186/s12931-021-01921-7] [Reference Citation Analysis]
2 Taha N, Hosein K, Grant-Orser A, Lin-Shaw A, Mura M. TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience. Pulm Pharmacol Ther 2021;66:101988. [PMID: 33406412 DOI: 10.1016/j.pupt.2020.101988] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mura M. Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. Pulm Pharmacol Ther 2021;66:101987. [PMID: 33387612 DOI: 10.1016/j.pupt.2020.101987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]